BTG (LON:BTG)‘s stock had its “hold” rating reissued by Deutsche Bank in a report released on Monday.
A number of other equities analysts have also weighed in on the stock. Numis Securities restated a “buy” rating on shares of BTG in a research report on Friday, September 7th. Shore Capital restated a “buy” rating on shares of BTG in a research report on Friday, September 7th. Peel Hunt restated a “hold” rating on shares of BTG in a research report on Tuesday, September 4th. JPMorgan Chase & Co. restated a “neutral” rating and set a GBX 650 ($8.47) target price on shares of BTG in a research report on Tuesday, August 21st. Finally, Royal Bank of Canada restated an “underperform” rating and set a GBX 510 ($6.64) target price on shares of BTG in a research report on Wednesday, June 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. BTG presently has a consensus rating of “Hold” and an average price target of GBX 697.50 ($9.09).
Shares of LON:BTG opened at GBX 564.50 ($7.35) on Monday. BTG has a fifty-two week low of GBX 559.82 ($7.29) and a fifty-two week high of GBX 784 ($10.21).
BTG Company Profile
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
See Also: Hedge Funds Explained
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.